Silver Spring, MD, December 17, 2012 --
Yesterday, the FDA held a public hearing to obtain input on certain questions related to the implementation of the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking Prevention and tobacco Control Act (FSPTCA). CASAA President Elaine Keller spoke on behalf of the organization. Also presenting before the FDA panel* as private citizens or as representatives of other organizations were CASAA's Legal Policy Director Gregory Conley, CASAA's Scientific Director Carl V Phillips, and CASAA advisor Bill Godshall.
The hearing was held for the FDA's consideration of new regulations regarding already approved smoking cessation products such as gums, patches and lozenges (NRTs) and the possible "fast tracking" of innovative new products that are intended to promote 1) total abstinence from tobacco use, 2) reductions in consumption of tobacco, and 3) reductions in the harm associated with continued tobacco use.
READ ENTIRE ARTICLE:
CASAA: CASAA testifies at FDA hearing
Yesterday, the FDA held a public hearing to obtain input on certain questions related to the implementation of the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking Prevention and tobacco Control Act (FSPTCA). CASAA President Elaine Keller spoke on behalf of the organization. Also presenting before the FDA panel* as private citizens or as representatives of other organizations were CASAA's Legal Policy Director Gregory Conley, CASAA's Scientific Director Carl V Phillips, and CASAA advisor Bill Godshall.
|
| Dr. Carl Phillips, CASAA Science Director speaking at FDA hearing |
READ ENTIRE ARTICLE:
CASAA: CASAA testifies at FDA hearing
